Thus, the 30-40% decrease in mRNA levels of cyclin A2/B2 following ORC6 silencing or knockout in primary glioma cells, as shown in Fig. 7, could be a secondary effect resulting from the 30-40% reduction in the S phase depicted in Fig. 4. The gene discussed is CCNA2; the disease is central nervous system cancer.